SpliceBio, a clinical-stage genetic medicines company, announced that it has dosed the first patient in the phase ½ Astra ...

The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

The therapy, OCU410ST (AAV-hRORA), represents a novel approach in treating Stargardt disease through a one-time ... advance in the field of genetic eye diseases, addressing a critical unmet ...

Casey Ophthalmic Genetics Division at Oregon Health & Science University Casey Eye Institute and Principal Investigator of Phase 1/2 ASTRA Study, commented: "Stargardt disease is a devastating ...

The biotech’s lead program is in preclinical development for Stargardt disease, a rare eye disorder caused by multiple genetic mutations. Kathy Bleitz suffers from a condition called Stargardt ...

A teenager diagnosed with a rare genetic eye disease which means she will lose her eyesight is desperate to see the world ...